For non-commercial studies carried out in England, the HRA activity statement may be used as an agreement between the sponsor and a participating website and may be sent to the HRA website. The MCTA is a standard contract that must be used without modification by sponsors of clinical trials and NHS/HSC organisations. Previously, according to the 2011 version, separate agreements were needed for each of the four nations – England, Scotland, Wales and Northern Ireland. The new proposal makes it possible to use a single agreement throughout Britain and streamline the process for companies wishing to carry out clinical trials at several sites. These model agreements apply to health services in England, Northern Ireland, Scotland and Wales; They replace the national versions of 2011. The accompanying guidance notes provide more general information, an overview of changes from the 2011 versions, and other information on how the models should be used and under what circumstances. The Health Research Authority (HRA) in England and health services in the demandised administrations expect sponsors (and CROs) to use the February 2018 MCTAs without modification and in accordance with the guidelines when entering into contracts with NHS/HSC organisations to carry out industry-sponsored studies. Similarly, NHS/HSC organisations are expected to accept unchanged MCTAs without further consideration of standard model elements. Contracts and agreements should be concluded before the start of the review and be subject to regular review to ensure that they remain up-to-date and relevant. All clinical trials and clinical trials (including CTIMP, device studies, etc.) should be subject to a signed agreement between the sponsor and the host organisation prior to the commencement of on-site research. The content of contracts and agreements should include: the Standard Clinical Trials Agreement for Primary Care Research sponsored by the biopharmaceutical industry (Primary Care mCTA) has been developed by the Association of the British Pharmaceutical Industry, the BioIndustry Association, a number of highly active GPs, the British Medical Association, the Medical Protection Society and the UK Health Services, and Okay. The Health Research Authority (HRA) supports the use of model agreements.